Northwell Health Cancer Institute appoints leader in robotic pancreas surgery

The Northwell Health Cancer Institute has chosen Steven Mitchell Cohen, DO, as its director of robotic pancreas surgery. Northwell has one of the largest cancer programs in New York State. Renowned for his expertise in the field, Dr. Cohen will further differentiate Northwell’s treatment of pancreatic disease with an emphasis on robotic Whipple procedures.

The Whipple is a complex surgery involving the pancreas, small intestine, gallbladder and bile duct. Dr. Cohen will report to Matthew J. Weiss, MD, MBA, vice president and vice chair of surgical service line, deputy physician-in-chief, and director of surgical oncology at Northwell Cancer Institute, and work to ensure that the program achieves new heights in excellence and innovation.

“We’re excited to add such an experienced leader in pancreas surgery, someone who has performed a high level with excellent outcomes on the leading edge of pancreatic cancer,” said Dr. Weiss. “The Whipple operation is already performed in high volume both robotically and open at Northwell Health. We’re confident Dr. Cohen will take this program to the next level.”

Prior to joining Northwell, Dr. Cohen served in roles at NYU Langone, from its gastrointestinal cancer management group to general surgery, as well as his involvement in Surgical Oncology NYC Health + Hospitals/Bellevue and NY Harbor VA Health Care System. Over the past five years, he focused extensively on robotic Whipple surgery in the Division of Hepatobiliary and Pancreatic Surgery. Dr. Cohen is board certified in general surgery and surgical critical care/trauma by the American Board of Surgery.

“The goal is to convert the more complicated pancreas surgeries to robotic procedures,” said Dr. Cohen. “Robotic pancreas Whipple surgery is preferable because it’s less invasive, there’s less blood loss and patients will experience less pain post-op. The robot allows for a great deal of suturing and stitching, similar to what I can do during an open surgery. And the visual is very impressive since you can see it in 3D. Additionally, the patient’s hospital stay will be shorter, and they’ll experience a slightly shorter healing process.”

Dr. Cohen received a Bachelor of Science degree from University of Arizona. He went on to earn his medical degree from Kirksville College of Osteopathic Medicine and completed his postdoctoral training, residencies and internships at Brookdale University Hospital in Brooklyn.

In recognition of his achievement in the field of robotic pancreas surgery, Dr. Cohen received the Mentor, Resident Grant Award from the American Pancreatic Association. His writings have appeared in such prestigious publications as Annals of Surgery and Pancreas in 2024, Journal of the American College of Surgeons, and the Journal of Surgical Oncology, to name a few.

Dr. Cohen will perform robotic Whipple procedures at Long Island Jewish Medical Center in New Hyde Park, Lenox Hill Hospital in Manhattan and South Shore University Hospital in Bay Shore.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”